Latanoprost

Generic Name
Latanoprost
Brand Names
Iyuzeh, Rocklatan, Xalacom, Xalatan, Xelpros, Catiolanze
Drug Type
Small Molecule
Chemical Formula
C26H40O5
CAS Number
130209-82-4
Unique Ingredient Identifier
6Z5B6HVF6O
Background

Latanoprost is a prodrug analog of prostaglandin F2 alpha that is used to treat elevated intraocular pressure (IOP). It was initially approved by the FDA in 1998. Latanoprost is the first topical prostaglandin F2 alpha analog used for glaucoma treatment. It has been found to be well-tolerated and its use does not normally result in systemic adverse effects l...

Indication

Latanoprost is indicated for the reduction of elevated intraocular pressure in patients who have been diagnosed with open-angle glaucoma or ocular hypertension. It is available as monotherapy or in a combination product with netarsudil or timolol.
...

Associated Conditions
Increased Intra Ocular Pressure (IOP), Ocular Hypertension, Open Angle Glaucoma (OAG)
Associated Therapies
-
Clinical Trials
Related News

A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).

Phase 3
Completed
Conditions
Ocular Hypertension
Glaucoma
Interventions
Drug: Xalatan
Drug: Xalacom
First Posted Date
2006-10-02
Last Posted Date
2021-09-08
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
300
Registration Number
NCT00383019
Locations
🇯🇵

Ohtsuka Eye Clinic, Sapporo, Hokkaido, Japan

🇯🇵

Kobe University Hospital, Koube, Hyogo, Japan

🇯🇵

Kanazawa university hospital, Kanazawa, Ishikawa, Japan

and more 51 locations

Safety And Efficacy Of Xalatan Delivered Using Either A Conventional Dropper Bottle or A Delivery Device

Phase 3
Withdrawn
Conditions
Glaucoma, Open-Angle
Ocular Hypertension
First Posted Date
2006-01-30
Last Posted Date
2021-02-02
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Registration Number
NCT00283764

A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma

Phase 3
Completed
Conditions
Open Angle Glaucoma
Ocular Hypertension
First Posted Date
2006-01-16
Last Posted Date
2021-02-18
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
528
Registration Number
NCT00277498
Locations
🇺🇸

Pfizer Investigational Site, Seattle, Washington, United States

Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension

Phase 3
Completed
Conditions
Ocular Hypertension
Glaucoma, Open Angle
First Posted Date
2005-09-22
Last Posted Date
2021-02-18
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
240
Registration Number
NCT00219596
Locations
🇨🇳

Pfizer Investigational Site, Shanghai, China

A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma

Phase 3
Completed
Conditions
Glaucoma, Open-Angle
Ocular Hypertension
First Posted Date
2005-09-12
Last Posted Date
2021-02-21
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
500
Registration Number
NCT00159653
Locations
🇨🇦

Pfizer Investigational Site, Saskatoon, Saskatchewan, Canada

A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension

Phase 3
Completed
Conditions
Glaucoma, Open-Angle
Ocular Hypertension
First Posted Date
2005-09-08
Last Posted Date
2008-11-05
Lead Sponsor
Pfizer
Target Recruit Count
976
Registration Number
NCT00150267
Locations
🇬🇧

Pfizer Investigational Site, London, United Kingdom

Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh.

Phase 4
Completed
Conditions
Glaucoma
Ocular Hypertension
First Posted Date
2005-09-02
Last Posted Date
2021-02-21
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
250
Registration Number
NCT00143208
Locations
🇮🇹

Pfizer Investigational Site, Sassari, Italy

Corneal Versus Conjunctival Delivery Using a Delivery Device

Phase 2
Withdrawn
Conditions
Ocular Hypertension
Glaucoma, Open-Angle
First Posted Date
2005-09-02
Last Posted Date
2021-02-02
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Registration Number
NCT00143429

A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma

Phase 4
Completed
Conditions
Ocular Hypertension
Glaucoma, Open Angle
First Posted Date
2005-08-31
Last Posted Date
2021-02-18
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
238
Registration Number
NCT00140049
Locations
🇸🇪

Pfizer Investigational Site, örebro, Sweden

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Phase 3
Completed
Conditions
Glaucoma, Open-Angle
Ocular Hypertension
First Posted Date
2003-01-07
Last Posted Date
2008-08-05
Lead Sponsor
Alcon Research
Registration Number
NCT00051142
Locations
🇺🇸

Latin America, Fort Worth, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy